Sun Pharma’s $4B Ranbaxy Buy Brings Consumer Products Business With New Growth Focus
This article was originally published in The Tan Sheet
In a landmark deal that fits the “made-for-each-other” tag, India’s Sun Pharma agreed to acquire all of Ranbaxy in a $4 billion transaction. While Ranbaxy can hope for a fresh lease on life with tighter regulatory operations under Sun Pharma, analysts said Sun needed to go for a big catch to sustain growth momentum.
You may also be interested in...
Marketing exclusivity would be a key advantage as Nexium 24HR enters a crowded market of branded and private label OTC competitors. The NDA for Nexium 24HR included clinical data, Pfizer says, but whether FDA allowed Hatch-Waxman Act exclusivity for the product is not yet determined.
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.
As Medicare drug price negotiations creep closer to reality, industry leaders are turning attention to the challenges of implementation and commercial concerns.